Phase 2 of Promising FA Trial to Begin!
The FA community received FANTASTIC new this week! Reata Pharmceuticals, who is focusing on correcting mitocondiral disfunction which causes the symptoms of Friedreich's Ataxia (FA) in the RTA 408 trial, is moving to the next phase in research.
Emory University is recruiting patients with Friedreich's Ataxia (FA) in the United States for a Phase 2 clinical trial studying the safety and effects of RTA 408 (a semi-synthetic triterpenoid, a Nrf2 activator with antioxidant properties) in FA. This study is sponsored by Reata Pharmaceuticals, Inc. This study includes several sites around the United States, including Emory University.
Reata is working with many doctors, including my doctor with the Friedreich's Ataxia Research Alliance (FARA) at the Children's Hospital of Philadelphia (CHOPS), Dr. David Lynch. How cool is that?!
To learn more about this study, watch the interview Kyle Bryant conducted with Reata Pharmaceuticals Chief Medical Officer, Dr. Colin Meyer here. Also, see the trial information and announcement here.
If you are an FA patient and haven't done so already - I urge you to register for the FA Patient Registry. That way, you will get the latest information regarding FA trials and see if you are eligible to participate in trials. You can register here.
Once again, all of this is possible due to the support of our awesome FA community. To help us continue moving forward, donate to Team Kendall. 100% of Team Kendall donations go to FARA.